⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MDCX News
Medicus Pharma Ltd. Common Stock
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
globenewswire.com
MDCX
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings
accessnewswire.com
BSIN
CAST
COCH
DVLT
LTRN
MDCX
VTIX
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
globenewswire.com
MDCX
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group
accessnewswire.com
MDCX
CAST
YYGH
LTRN
DVLT
BSIN
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
globenewswire.com
MDCX
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
accessnewswire.com
AERT
VTIX
DVLT
IGC
MDCX
NRXP
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
globenewswire.com
MDCX
New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA
accessnewswire.com
COCH
DVLT
RDZN
MDCX
IGC
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
globenewswire.com
MDCX
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
globenewswire.com
MDCX